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Effectiveness of opportunistic screening 
for cancer of the cervix uteri
Abstract
The incidence and mortality of uterine cervical cancer in 
the Maltese Islands has remained relatively constant in medical 
records of the last few decades. The aim of this study was to 
determine the cervical cancer screening history and other 
characteristics of the invasive cervical cancer cases diagnosed 
in Malta between 1992 and 2002, from a review of their medical 
records.  Only 5% of the cases reviewed had had regular cervical 
smears prior to the diagnosis of the invasive lesion.
Well organised national cancer screening programmes 
overseas indicate that if less than 70% of the target population 
(ages 20 to 65 for cervix) is regularly screened, the incidence 
and mortality will not decrease.1  In Malta, cervical screening 
is opportunistic and the percentage and sectors of the target 
population being screened is unknown.  A national study is 
needed to quantify the number of women undergoing cervical 
screening and to assess how much of the relevant target 
population is being screened.
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Introduction
Following breast cancer, invasive cancer of the uterine cervix 
is the second most common type of cancer in women worldwide.2 
Annually, about 471,000 new cases and 190,000 deaths are 
reported globally.2 It is estimated that more than 12,800 women 
in the European Union die each year from the disease.3 In Malta, 
between 1992 and 2002, 132 new cases of cervical cancer and 
49 deaths from this cancer were reported.4 In many countries 
cervical cancer is the commonest pelvic gynaecological organ 
cancer. In Malta, however, cancer of the uterine cervix is the 
third most common cancer of the female genital organs. It is 
preceded by cancers of the body of the uterus and ovaries.
Overview of Cervical Cancer Screening
Cervical cancer was the first malignancy world-wide for 
which an effective method of screening was introduced. Direct 
evidence from randomized clinical trials to support the value of 
the cervical smear in reducing mortality from cervical cancer is 
scarce. However, a huge body of indirect evidence suggests that 
this inexpensive test may be among the most effective screening 
techniques available.5
Quantitative studies have shown an 84% reduction in cancer 
incidence by screening women aged 35-64 years every 5 years, 
which increases to 91% if screening is undertaken every 3 years. 
Screening more frequently (every 1-2 years) did not appreciably 
reduce incidence further (93%).6 
A national screening programme would entail testing invited 
women, in pre-defined age groups, at pre-defined intervals, in 
contrast to opportunistic screening done only on the initiative 
of the subjects themselves, or of their private doctors.  The 
EU recommendations on cancer screening7 declare that for 
optimization of a screening programme (in terms of cost 
effectiveness), high level of coverage with regular tests at defined 
intervals in the age group at greatest risk, is needed.
Efficient national screening programmes exist in various 
countries, including Scandinavian/Nordic countries such as 
Finland, Sweden and Iceland. The programmes were started 
between 1963 and the mid-1970s. Soon after the introduction 
of these programmes, there were large decreases in cervical 
cancer incidence and later mortality rates. The decrease was 
confined largely to the age groups 30–59 years, i.e to those 
groups targeted in the programmes.8 
A similar national screening programme was started in the 
UK in the early 1960s.  However, after about two decades (1960–
1986) of British NHS cervical screening service, the mortality 
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from cervical cancer, although not rising, was not decreasing.9 
The reason for this less effective UK cervical screening was 
tracked down to the fact that only a small proportion of the 
women at risk were being screened. 
The British screening programme was remodeled in 1988, by 
introducing a computerized call and recall system for invitations, 
new quality standards, and the adoption of a 3 year screening 
interval rather than the previous 5 year interval. Subsequently, 
the effectiveness of this screening programme with regards to 
cervical cancer incidence and mortality improved markedly10. 
In England and Wales, there are approximately 2700 cases of 
invasive cervical cancer per year, and approximately 19000 in 
situ cancers registered per year, with approximately 1200 deaths 
per annum. The incidence had fallen from 16 per 100 000 in 
1986 to 9.3 per 100 000 in 1997. Moreover mortality rates have 
fallen at about 7% per annum.3
Since 1978, the public primary health care centres in Malta 
and St. Luke’s Hospital have offered a free cervical cytology 
screening service. Also, most of the private laboratories also 
provide a similar service against payment. To date, there is 
still not an organized national cervical screening programme 
in place, and hence all the cancer screening activity in Malta is 
opportunistic in nature.
The number of women availing themselves of these 
services is not known.  A question focused on the screening 
attitudes of Maltese women from the National Health Interview 
Survey (NHIS), held in 2002, revealed that 41% of the women 
interviewed reported that they had never had a cervical smear 
test.11
In view of the rate of cervical cancer incidence and mortality 
in recent years, it is thought that only a small proportion of the 
female population at risk is actually being screened. 
Aim
The aim of this study was to determine the cervical cancer 
screening experience of the cases diagnosed with invasive 
cancer of the uterine cervix in Malta during the time period 
1992-2002. 
Materials and Methods
The St. Luke’s hospital (SLH) files of the patients diagnosed 
with invasive cervical cancer between 1992-2002 (n=132) were 
reviewed. These cancer cases were extracted from the Malta 
National Cancer Register. This cancer registry collects and 
analyses information on cancer diagnoses performed on all 
residents of the Maltese Islands. The registry utilizes a number 
of both passive and active methods for data collection such 
that multiple sources of data are employed for any registration 
of cancer. Information sought and extracted included any 
information related to the patient’s sexual lifestyle habits 
and their smear history. Any documented cervical smears 
performed prior to the diagnosis of the invasive lesion (if any), 
their frequency and their results were noted. Other information 
collected included the locality of residence at the time of 
presentation and the tumour histological type, differentiation 
and stage at diagnosis.
Ninety two patient files out of the 132 in the study population 
were viewed. Out of the files viewed, 77 were of patients still alive 
whilst 15 were of patients who had subsequently died. Forty files 
could not be retrieved, 6 of these were of patients still alive and 
the remaining 34 were of deceased cases. 
Apart from the file review, the results of the National Health 
Information Survey (NHIS) will be cited in this study. This is 
being done in order to serve as a comparison with the results 
of this study.
The NHIS was performed in 2002 by the Department 
of Health Information. It was conducted at a national level 
involving a randomly selected sample of 5510 individuals, of 
which 2213 were women, aged 16 years and over currently 
residing in the Maltese Islands. The sample has been drawn 
from a population register and has been stratified by age, gender, 
and locality to ensure as representative a sample as possible to 
the general adult population. The design of the questionnaires 
involved the use of survey instruments already used in several 
surveys performed in other European countries with due 
consideration to the local context. This has been facilitated by 
collaboration with WHO/ EUROHIS project. The questions 
focused on various health topics, including one question 
focusing on cervical screening.10
 Age Number of Cases
 <24 0
 25-34 9
 35-44 36
 45-54 32
 55-64 26
 65-74 16
 75-84 8
 >85 5
 Total 132
Table 1: Cases of invasive cervical cancer 
 1992-2002, by age groups 
 Parity Number of Cases  
 Nulliparous 11 
 1 13 
 2 19 
 3 15 
 4 4 
 5 3 
 6 3 
 >6 7 
 No information 18
Table 2: Cases of invasive cervical cancer 
 1992-2002, by parity 
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Results
Age distribution and sexual lifestyle
Table 1 shows the cases of cervical cancer patients 
investigated in this research by age groups. Diagnosis of this 
condition was commonest in the peri-menopausal age groups. 
However, cases continue to present even later in life and in 
old age. About 7% of cases presented at or before the age of 
34 years. 
The median age at diagnosis was 52 years, while the median 
age at death was 55 years. The underlying cause of death of 
83% of the deceased cases was invasive cancer of the uterine 
cervix. 
The information available in the hospital files of these cases 
related to the sexual lifestyles of these cases was practically 
non-existent. The only data that was often documented was 
related to their parity. Eighty (80%) percent of the files reviewed 
recorded this variable. Table 2 illustrates the findings with 
regards to parity.   
Smear History
Only 54% (50/92) of files of patients with invasive cervical 
cancer had information about the patients’ smear history. 
Smear results found in these files were those performed at St. 
Luke’s Hospital and did not include those which could have 
been performed in private laboratories. However in some of 
the cases there were notes which indicated that the patient had 
performed smears in private laboratories.
Of the 50 files which had information regarding smear 
history, 44% (22/50) did not have any reported smears prior 
to the diagnosis of the invasive lesion, 46% (23/50) had rare 
smears (1 or 2 smears found) and only 10% (5/50) had regular 
smears (once every 3 years). In the 5 cases with regular smears, 
no pre-cancerous lesions were detected in the smears prior to 
the detection of the invasive lesion. 
Regional differences of incidence 
of Invasive Cervical Cancer
The cases in this study were divided into the 6 census regions 
used in 1995.11 Table 3 shows the cases reviewed in this study 
by the region corresponding to their locality of residence at the 
time of presentation with invasive cervical cancer.
Statistical analysis was performed to compare cervical cancer 
incidence in the 6 regions. Standardised incidence ratios (SIR) 
were constructed; using the indirect standardization method and 
STATA statistical software and confidence interval (95%) was 
calculated around them using the following formula:
Var = Σ w
j
2     cases
j
                         pap2
j
Regions 1 and 2 which include the most densely populated, 
urbanised and industrialized regions of the Maltese Islands 
showed significantly higher incidence than the national 
incidence rate. On the other hand, regions 4, 5 and 6 which are 
the northern and the more predominantly rural areas showed 
significantly lower incidences. 
Tumour morphology and stage at diagnosis 
Squamous-cell carcinoma and adenocarcinoma are the 
most commonly occurring histological types of cervical cancer, 
and account for approximately 80% and 15% of all cases, 
respectively.12 In our series, 78% had squamous-cell carcinomas, 
11% had adenocarcinomas, and there was a case each of small 
cell carcinoma, adenosarcoma, rhabdomyosarcoma (arising in 
the cervix of an adolescent girl) and malignant mesonephroma. 
These last 2 cases were excluded from the study. For ten of 
the cases (7.6%), the diagnosis established that there was a 
carcinoma but the type of malignancy was not further identified 
in the histological reports. All but 2 of the cases in this series 
had microscopical verification of their tumour. These two cases 
were older than 85 years at diagnosis and they were registered 
on the basis of a clinical diagnosis only.
Tumour stage has long been recognized as the most 
important determinant of outcome in patients with cancer of 
the cervix.12  Reviewing the histologies, operative reports and 
radiological examinations available in the patients’ files the 
researchers endeavored to stage the cancers at diagnosis. From 
the information available, the staging exercise was possible only 
in 52.3% (69/132) of cases. Of these, 40 cases were at FIGO 
Stage I at diagnosis, 17 cases were at Stage II, 7 at Stage III and 
5 at Stage IV.
Number Region Number of Cases
 1 Inner Harbour  Region 44
 2 Outer Harbour  Region 40
 3 South Eastern Region 17
 4 Western Region 10
 5 Northern Region 11
 6 Gozo and Comino 10
  Malta, Gozo and Comino 132
Table 3: Cases of Invasive Cervical Cancer by Region
Region Observed SIR Exp UCL* Exp LCL** 
 1 44 1.27 1.28 1.27 
 2 40 1.04 1.04 1.03 
 3 17 1 1.01 1 
 4 10 0.56 0.57 0.56 
 5 11 0.82 0.82 0.82 
 6 10 0.83 0.84 0.83
* Exponential Upper Confidence Limit   
** Exponential Lower Confidence Limit
Table 4: Standarised incidence ratios of cases by region   
 related to locality of residence at time of diagnosis
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Discussion
Mortality and incidence rates of invasive cervical cancer 
in the last 36 years in Malta maintained a steady trend, with 
minor fluctuations.13  Evaluation of these rates did not reveal 
any statistically significant changes in the incidence of (p=0.88), 
and mortality from (p=0.38), cervical cancer.  Figures 1 and 2 
show graphical illustrations of these temporal trends over the 
last four decades.
The information obtained in this review, regarding the smear 
history of the women diagnosed with invasive cervical cancer 
between 1992-2002, compares well with the findings on the 
reported smear history of women that were interviewed in the 
NHIS conducted in 2002.  In this survey, 2213 women at and 
above the age of 16 years, were interviewed and asked about 
“when was the last time you had a cervical smear?”.  Only 
45.2% reported having had a smear test in the 3 years prior 
to the survey.  The remaining respondents included 41% who 
reported never having had a smear test, and 13.8% reporting 
that their most recent smear was performed more than 3 years 
prior to the survey.  The EU recommendations on cervical cancer 
screening, as well as the practices followed in most organized 
screening programmes, advise that cervical smear testing should 
be performed every 3 years.  The findings of our study, together 
with the results of the NHIS, indicate that this practice is not 
being adhered to in Malta.  
Table 5 illustrates the results from the NHIS on cervical 
smear activity by age groups.  Women in the age group 25–44, 
followed by the 45–64 age group, are those who are being 
screened most. Reported screening activity in women over the 
age of 65 and below the age of 25 years was very low.
The regional analysis of the cases reviewed in this study 
showed that incidence was higher in regions 1 and 2 of the 
Maltese Islands.  Table 6 shows information extracted from 
the NHIS corresponding to reported smear history of the 
interviewed women by regions that include their locality of 
residence.
NHIS showed that more women from regions 4 and 5 had 
a smear in the last 3 years, than women from regions 1, 2, 3 
and 6.  The percentage of women who never had a smear was 
greatest in regions 1 and 6.  This is reinforced by adding those 
women who never had a smear test with those who never had 
 Age 16-24 25-44 45-64 65-74 75+ All ages
 <3 yrs 22.10% 68.60% 51.00% 11.60% 5.80% 45.10
 >3yrs 0.70% 13.30% 19.40% 17.60% 9.10% 13.80
 Never  77.20% 18.10% 29.60% 70.80% 85.10% 41.10
 No Screening* 77.90% 31.40% 49.00% 88.40% 94.20% 54.90
* > 3 yrs and never screened 
Table 5: Cervical Screening by Age Groups (NHIS, 2002) 
 Region 1 2 3 4 5 6 All regions
 <3 yrs 35.73% 47.17% 46.33% 50.33% 53.39% 35.34% 44.98
 >3yrs 15.90% 13.94% 11.18% 12.75% 15.30% 10.78% 13.78
 Never  48.37% 38.90% 42.49% 36.91% 31.32% 53.89% 41.24
 No Screening* 64.27% 52.84% 53.67% 49.66% 46.62% 64.67% 55.02
* > 3 yrs and never screened 
Table 6: Cervical Screening by Regions (Source: NHIS, 2002) 
Figure 1: Incidence of Invasive Cervical Cancer 
 by year (using Total Crude Rates)
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Figure 2: Mortality of Invasive Cervical Cancer 
  by year (using Total Crude Rates)
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a smear test in the last 3 years.  This review showed that the 
cases of invasive cervical cancer in Malta tend to reside most 
commonly in regions 1 and 2 (see Table 3).  Interpreting this 
finding together with the lower rates of smear activity reported 
by women in the NHIS residing in the same regions, suggests 
that women at higher risk for the invasive condition are not 
being effectively reached by the current screening activity in 
the Maltese Islands.
Interestingly, women residing in region 6 reported the 
lowest level of cervical screening activity.  Contrastingly, this 
review also showed that the incidence rate for invasive cervical 
cancer in Gozo is statistically significantly lower than the 
national rate.  These anomalous findings may be tentatively 
and partially explained by possible different attitudes of Gozitan 
women regarding sexual practice.  The NHIS data shows that 
Gozitan women report very low rates of multiple sexual partners 
(0% of women reported having multiple sexual partners, while 
35% declined to answer the relevant question).    
Just over half the cases of cervical cancer had a smear history 
in their files. Improving the smear history documentation of all 
gynaecological referrals, and especially of patients presenting 
with cervical-related symptoms and pathology, will help towards 
more accurate evaluation of the effect of screening activity. In 
2004, a new cervical smear request form was introduced for the 
Primary Health Care Centres.  This includes appropriate fields 
for the gynaecologist to document the number and regularity/
pattern of cervical smears undertaken by women attending these 
clinics.  However, request forms from the hospital facilities in 
both Malta and Gozo have retained the old format.  Updating of 
similar forms used by private laboratories should be encouraged. 
This is important since the majority of the cervical smear tests 
in Malta are performed by the private sector. 
Although an opportunistic cervical screening programme in 
the public sector has been in place since 1978, no national studies 
have been performed to quantify the amount and characteristics 
of women who are being attracted to do routine cervical smear 
tests. This is also true in the case of private laboratories where 
a considerable amount of smears are done every year. Till now 
there are no relevant statistics about the amount of smears done 
yearly in the private sector. 
EU recommendations state that when screening is to be 
undertaken, it should only be offered in organized programmes 
with quality assurance at all levels, and good information about 
the benefits and risks.  The benefits of a screening programme 
are only achievable if the target population coverage is high. 
Opportunistic screening activities are usually not acceptable 
as they may not achieve the potential benefits and may cause 
unnecessary negative side-effects.7
The major aim of cervical screening is to decrease incidence 
and mortality of invasive cervical cancer.  The audit information 
presented shows that there was no significant decrease in 
incidence and mortality of cervical cancer in Malta over time, 
in spite that cervical screening services have become more 
available and accessible in the last 2-3 decades.  The percentage 
of the female target population being screened is unknown, and 
the effectiveness of this Maltese opportunistic cervical cancer 
screening is therefore questionable.
The mortality rate also maintained a steady trend with minor 
fluctuations, reinforcing doubts about the effectiveness of the 
screening activity since it is not detecting the precancerous 
lesions or the invasive lesions at curable stages to increase 
survival.
Women at higher risk for cervical cancer due to their 
lifestyles, especially sexual practices, are known to be more 
likely not to present for cervical screening.14,15  Screening that 
concentrates solely on a high-risk group is rarely justified, as 
identified risk groups usually represent only a small proportion 
of the cancer burden.  In planning the coverage (target 
population) of screening programmes, however, steps must be 
taken to ensure that all those at high risk are included.  This 
is often a difficult requirement to fulfill.16  Health promotion 
directed at women’s health should focus on increasing the 
frequency and scope of campaigns promoting the advantages 
of cervical screening in prevention of cervical cancer.
The situation in Malta is analogous to that in the UK before 
1988.  After more than two decades (1960–1986) of British NHS 
cervical screening service, the mortality from cervical cancer, 
although not rising, was not decreasing.  It was established 
that this screening service was largely opportunistic and that 
the percentage of the target female population (ages 20 to 65) 
being regularly screened was unknown.  It was also established 
that regular screening of more than 70% of the target population 
was needed to decrease invasive cervical incidence and 
mortality.  Remodeling of the programme in 1988 resulted in 
a 34% decrease in the incidence of cervical cancer and the age 
standardized mortality decreased from 6.1 per 100,000 in 1987 
to 3.7 in 1997.1  The crucial remodeling feature was introduction 
of an incentive for family doctors to screen at least 90% of the 
target female population (ages 20 to 65).
Also until now there is no standardized system in the 
reporting of smears in Malta. The dyskaryosis/cervical 
intraepithelial neoplasia (CIN) classification is still very much 
in use. The Bethesda system was developed by the United 
States National Cancer Institute (NCI) to provide more detailed 
information about cervical smear results. Apart from giving 
information regards descriptive diagnosis when there is an 
abnormality in a smear, it also provides information about the 
quality of the cell sample and criteria for smear suitabality. 
The Bethesda system has been introduced in many European 
countries, and has become the most popular classification in 
the reporting of cervical smears. Standardization of cervical 
smear reporting by choosing one system by which all smears are 
reported both in the public and private sector can result in less 
confusion and facilitate research audits about the subject.17 
In conclusion, we suggest a national study to quantify the 
number of women undergoing regular cervical screening so 
that the percentage of the target population being screened is 
established. This study should include all the public and private 
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clinics/hospitals that offer cervical screening in Malta and Gozo, 
so that an accurate estimation can be obtained. The researchers 
have to collect information about the cervical smears submitted 
to the laboratories for a specified time period. It is important that 
all private laboratories/clinics will support this study to increase 
its accuracy. The results of such a study can show a clear picture 
of the situation of cervical screening activity in Malta. It can be 
used to assess the situation, identify problems of attendance in 
specific age groups and any regional discrepancies, if present 
and finally to propose changes to improve the uptake of cervical 
screening on the Islands. 
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